RECEIVED

AUG 0 1 2001#3 TECH CENTER 1600/2900 APPLICATION NO. ATTY. DOCKET NO. 09/769,420 1735.0440001/RWE/BEC FORM PTO-1449 APPLICANTS Cai et al. ON DISCLOSURE STATEMENT GROUP FILING DATE January 26, 2001 1614 U.S. PATENT DOCUMENTS EXAMINER NAME CLASS SUB-FILING DATE DOCUMENT DATE INITIAL CLASS NUMBER Schmidt 260 239.3 12/06/1966 10/15/1968 AA1 3,406,168 71 04/14/1981 Bollinger et al. 94 08/09/1978 AB1 4,261,730 514 620 02/27/1997 02/22/2000 Pero et al. AC1 6,028,111 AD1 AE1 AF1 AG1 AH1 AI1 AJ1 AK1 FOREIGN PATENT DOCUMENTS EXAMINER COUNTRY CLASS SUB-TRANSLATION DOCUMENT DATE INITIAL CLASS NUMBER Yes No Yes No Yes No AN Yes No AO Yes No 11/19/1997 Europe AP1 0 807 633 A2 OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Atwell, G.J. et al., "Potential Antitumor Agents. VII. Bisquaternary Salts," J. Med. Chem. 11:300-305, American Chemical Society (1968) Balcells, M. et al., "Synthesis of Phenoxyphenyl Pyridine and Pyrazine Carboxamides. Activity against Cydia pomonella (L.) Eggs, " J. Agric. Food AS 9 Chem. 48:83-87, American Chemical Society (2000). Cooper, G.H. and Rickard, R.L., "Reductive Acylation of 5-Nitropyridines with Anhydrides of Acetic, Phthalic, and Succinic Acids," J. Chem. Soc. C 19:3257-<u>9</u> 3260, Chemical Society (1971)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DATE CONSIDERED

Ol

EXAMINER

RECEIVED

AUG 0 1 2001

	PE,	400						TEC	H CENTER	₽4600\$29 0 0
/	2000	M # 1				ATTY. DOCKET 1735.0440001		APPLI	CATION NO	-
11	3 1 201	<u>u-1</u>		PTO-1449		APPLICANTS Cai et al.		•		<u> </u>
PHENTE	INFO TRADEN	RMATIO	N DIS	CLOSURE STA	<u>ATEMENT</u>	FILING DATE January 26,	FILING DATE GROUP			
					v.s.	PATENT DOCUMEN				
EXAMINE	ER									
INITIAL			DOC	UMENT BER	DATE	NAME		CLASS	SUB- CLASS	FILING DATE
		AA2	1							
		AB2								
		AC2			<u> </u>					
		AD2	丄						<u> </u>	
		AE2	<u>.</u>		<u> </u>					
		AF2								
		AG2	 							
	_	AH2	-						<u> </u>	
		AI2			<u> </u>					
		AJ2	 		<u> </u>					
		AK2	<u> </u>						<u> </u>	<u> </u>
		T	1		FOREIG	N PATENT DOCUME	INTS		Γ -	T
EXAMINER INITIAL			DOCUMENT NUMBER		DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATION
ym		AL2	1 5	73 576	08/28/1980	Great Britain				Yes No
		AM2	2 2000-256358		09/19/2000	Japan				Yes √No
		AN2	wo_	99/24404	05/20/1999	WIPO				Yes No
		A02	wo	00/06550	02/10/2000	WIPO				Yes √No
9	/	AP2	WO	00/55114	09/21/2000	WIPO				Yes No
		1				Title, Date, P	ertinent Page	s, etc.)		
4	Z	AR	10	Photosynt	hesis-Inhibiti	rnthesis and Ant ng Evaluation on the Papers 54:245	of Some Anilid	les of Sul	stituted	Pyrazine-2-
Y	AS Doležal, M. et al., "Synthesis and Photosynthesis-Inhibiting Activity of Some Anilides of Substituted Pyrazine-2-carboxylic Acids," Chem. Papers 53:126-130, Veda (1999).								y of Some 3:126-130,	
T	N	AT	<u>10</u>	Antipsych	JF. F. et a otics: Synthes Chemical Socie	11., "New Pyrido is and Neuroche ty (1993)	obenzodiazepin emical Study,"	e Derivat J. Med.	tives as 1 Chem. 36	Potential :2107-2114,
EXAMINE	R	1/10	11	en /	11 1:11	η_i	D	ATE CONST	DERED G	
EXAMINE line th	R: I	nitial citat	if r	eference co	onsidered, whe	ther or not cit	ation is in co	onformanc py of thi	e with ME	PEP 609. Draw
communi										

RECEIVED

AUG 0 1 2001

TECH CENTER 1600/2900

							-0.1011	Ŧ Ĕ Ū 1 9 U#29U
1						APPLI	CATION NO	
<u>a j</u>				APPLICANTS Cai et al.				
RMATIO	N DIS	CLOSURE STA	TEMENT	FILING DATE January 26, 200	1	GROUP 1614		
			U.S.	PATENT DOCUMENTS				
			DATE	NAME	C	LASS	SUB- CLASS	FILING DATE
AA3								
AB3								
AC3	ļ							
AD3	1							ļ
AE3	_							
AF3								
AG3								
AH3	<u> </u>							
AI3								_
AJ3								
AK3	<u> </u>							
			FOREIG	N PATENT DOCUMENTS				
			DATE	COUNTRY	C	LASS	SUB- CLASS	TRANSLATION
AL3	WO	00/62778	10/26/2000	WIPO				Yes No
АМ3	WO	01/02354	01/11/2001	WIPO				Yes √No
AN3	WO	01/21598	03/29/2001	WIPO				Yes No
A03								Yes No
AP3								Yes No
	1	OTHER (Incl	uding Author,	Title, Date, Pert	inent Pages,	etc.)		
AR	11	Studies or (3',5'-bis	n the Pyrimidi (trifluorometh	ne Portion of 2-Ch yl)-phenyl)carboxi	loro-4-trifl	uoromet	hylpyrimi	dine-5-[N-
AS	<u>11</u>	Carboxamic Strain and	les: Inhibitio l a Carboxin-R	n of Complex II Ac esistant Mutant St	tivity in Mi rain of <i>Usti</i>	tochond	lria from	a Wild-Type
ат 1	11				onal Patent	Applica	ation	
	7//	W	We	l/	DAT	E CONST	DEKED Z	52
citat	ion i	f not in co	nsidered, when	ther or not citation not considered.	on is in con Include copy	formanq of thi	e with MP s form wi	EP 609. Draw th next
	AA3 AB3 AC3 AD3 AE3 AF3 AG3 AH3 AJ3 AX3 AX3 AX3 AX3 AX3 AX3 AX3 AX3 AX3 AX	FORM INTERPRETATION DISTRIBUTION DISTRIBUTIO	FORM PTO-1449 EMATION DISCLOSURE STA DOCUMENT NUMBER AA3 AB3 AC3 AD3 AE3 AF3 AG3 AH3 AI3 AJ3 AK3 DOCUMENT NUMBER AL3 WO 00/62778 AM3 WO 01/02354 AN3 WO 01/21598 AO3 AP3 OTHER (Incl Palanki, M Studies or (3',5'-bis American (Carboxamic Strain and Physiol. 3') AT 11 Internation No. PCT/US	TOTHER (Including Author, Palanki, M.S.S. et al., Studies on the Pyrimidi (3',5'-bis(trifluorometh American Chemical Socie White, G.A., "Substitut Carboxamides: Inhibitio Strain and a Carboxin-R Physiol. 34:255-276, Act of the citation if not in conformance and confor	FORM PTO-1449 EMATION DISCLOSURE STATEMENT PILING DATE January 26, 200 U.S. PATENT DOCUMENTS DOCUMENT NUMBER AA3 AB3 AC3 AD3 AD3 AC3 AD3 AD3 AC4 AC5 AC6 AC7 AC7 AC7 AC7 AC7 AC7 AC7	FORM PTO-1449 FORMATION DISCLOSURE STATEMENT DOCUMENT DATE NAME DOCUMENT NUMBER AA3 AB3 AB3 AC3 AB3 AF3 AF3 AF3 AF3 AF3 AF3 AF	ATT. DOCKET NO. 193/76 FORM PTO-1449 FORM PTO-144	ATT, DOCKET NO. 1735.0440001/RME/BEC 09/769,420 APPLICATION NO 09/769,420 ARGUE TILING DATE CLASS SUB-CLASS AB3 AB3 AB3 AB3 AB3 AB3 AB3

JUN 2 5 2001 TRADEM!

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1735.0440001/RWE/BEC APPLICATION NO. 09/769,420 APPLICANT CAI et al. GROUP

					January 26, 2001	1614		_ <u> </u>
				U.S.	PATENT DOCUMENTS			
EXAMINER INITIAL			UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	АВ							
	AC							
	AD							
	AE	<u> </u>						
	AF							
	AG	<u> </u>						<u> </u>
	АН	<u> </u>						
	AI			ļ				
	AJ							
	AK	<u> </u>			<u> </u>			
		1		FOREIG	N PATENT DOCUMENTS	 		
EXAMINER INITIAL		DOC NUM	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
94	AL1	WO	95/25723	09/28/1995	WIPO			Ye N
pi	AM1	WO	96/20721	07/11/1996	WIPO			Y ∈ 1
7	AN1	WO	99/36391	07/22/1999	WIPO			Ye
gn	A01	WO	00/44216	08/03/2000	WIPO			Ye N
,	AP '							Ye N
			OTHER (Inc.	luding Author,	Title, Date, Pertinent	Pages, etc.)		
HI	AR	<u>1</u>	Vivo Admi	nistration of	ene Therapy of Experimer Plasmid DNA Coding for ciation of Immunologists	Fas Ligand,"	J. Immuno	
M	AS	<u>1</u>	Gastroint	estinal Inflam	'Lamina Propria T Cells mmation Show Defective C -565, American Gastroent	D2 Pathway-Ir	duced Apo	ptosis,"
*	AT	1			JVA-induced lymphocyte atol. Phytoimmunol. Photo			
EXAMINER		\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	m)/// /	111	DATE CONS	IDERED / E	7/02
EXAMINER: 1	nitial citat	if r	eference co	onsidered, whe	ther or not citation is not considered. Inclu	in conforman de copy of th	ce with M	PEP 609. Dra ith next

FILING DATE

OIPE	10177 E			Ì				ובטו טב	Page 2	R L
JUN 2 5 201) <u> </u>				ATTY. DOCKET NO. 1735.0440001/RWE/BEC			CATION NO	7	H
TRADENA INFO	F'	ORM F	PTO-1449		APPLICANT		09/10			"
TRADEM	RMATION	1 DIS	CLOSURE STA	ATEMENT	CAI et al.			6	2001	$\overline{\mathbf{m}}$
					FILING DATE January 26, 2001		GROUP 1614	/29	, -	
				U.S.	PATENT DOCUMENTS				<u>; </u>	
EXAMINER INITIAL		DOCU NUME	UMENT BER	DATE	NAME	CL	ASS	SUB- CLASS	FILING	DATE
	AA								ļ	
	AB	 				+				
	AC	\vdash				+		 	 	
	AD AE	+				+		 	 	
	AF	 				+				
	AG	t	· · · · · · · · · · · · · · · · · · ·						 	
	АН						•			
	AI									
	AJ	<u> </u>				┷				
	AK	<u> </u>								
	Т	T		FOREIGN	N PATENT DOCUMENTS				т —	
EXAMINER INITIAL	ļ	DOCU	UMENT BER	DATE	COUNTRY	CL	ASS	SUB- CLASS	TRANSL	
	AL			· !						Yes No
	AM									Yes No
	AN								ı	Yes No
	AO									Yes No
	AP									Yes No
	AF	Щ,	OTHER (Incl	luding Author.	Title, Date, Pertinent Pag	des.	etc.)			110
4n	AR	<u>2</u>	Ellis, R.I	E. et al., "Me	chanisms and Functions of (Reviews, Inc. (1991).			" Annu. R	ev. Cel	1.
Tu	AS	<u>2</u>	in drug-i		volvement of the CD95 (APO- is in leukemia cells," <i>Nat</i> :					tem
Th	AT	<u>2</u>	Poly(ethy)	lene glycol) P: 667, American ("Drug Delivery Systems Emprodrugs of Amine-Containing Chemical Society (September	g Com	pounds	s," J. Med	i. Chem.	
EXAMINER) K (4	<i>DL</i>	MASI	D/////////////////////////////////////	Th.	DATE	CONSI	DERED8	u	-
EXAMINER: Vin	nitial citati	if re	eference co	msidered, whet onformance and	ther or not citation is in not considered. Include o	conf	ormand of the	e with MPI s form wi	EP 609. th next	Draw

JUN 2 5 2001 JUN 2 5 2001 FORM

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

		品	Page	₃ ∏	8
ATTY. DOCKET NO. 1735.0440001/RWE/BEC	APPLICATION 09/769,420	NÄEI	0		
APPLICANT CAI et al.		3 160	20	Z	:
FILING DATE	GROUP	200	01	П	

					January 26, 20	01 GROO 1614		
				Ū.	S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOC NUM	UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	AB	\bot						
· · · · · · · · · · · · · · · · · · ·	AC							
	AD			<u> </u>				
	AE			<u> </u>				
	AF							<u> </u>
	AG							
	AH							
	AI	+					 	
	AJ	+		_				
	AK	<u> </u>	· · · · · · · · · · · · · · · · · · ·		TION DAMENIE DOCUMENT	10		
EXAMINER	<u> </u>	1		FOR	EIGN PATENT DOCUMENT	.5	1	
INITIAL		DOC NUM	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
	AM							Yes No
	AN							Yes
	AO							Yes
	AP							Yes
	1		OTHER (In	cluding Auth	or, Title, Date, Per	tinent Pages, etc.)		
44	AR	<u>3</u>	Heenen, kerating	M. et al., " ocytes," Arch	Methotrexate induces	s apoptotic cell dea 0:240-245, Springer-	ath in hum -Verlag (1	an 998).
M	AS	<u>3</u>	lymphopi	coliferative	, "The clinical spec syndrome caused by a tr. 133:629-633, Mos	Fas mutation that		
Ta	AT	3	of Campt Prodrug	othecin for Therapy (ADE	Design and Synthesis Cancer Prodrug Monot PT)," J. Med. Chem. Published on Web, Aug	therapy and Antibody 42:3623-3628, Ameri	y-Directed	Enzyme
EXAMINER	M	NI	yac(2000	Ar-	DATE CONS	I DER PO	
EXAMINER: line through	n citat	tion i	f not in	considered, conformance	whether or not citat and not considered.	ion is in conforman Include copy of th	ice with M is form w	PEP 609. Drav ith next

JUN 2 5 2001 AND TRADEMARKORY

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1735.0440001/RWE/BEC 09/769,420 Page 4 6f 8

APPLICANT CAI et al.

FILING DATE January 26, 2001 GROUP 1614

					January 20, 2001	11014		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCU	UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	АВ							
	AC							
	AD							
	AE							
	AF							
	AG	ļ						
	AH							
	AI	ļ						
	AJ	ļ			·			
	AK	<u> </u>			<u> </u>			
	,	,		FOREIG	N PATENT DOCUMENTS	•		
EXAMINER INITIAL		DOCU	JMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
	AM							Yes No
	AN							Yes No
	AO							Yes No
	AP							Yes No
			OTHER (Incl	uding Author	Title, Date, Pertinent Page	etc)		
The	AR	<u>4</u>	López-Hoyo its role i	s, M. et al.,	"Regulation of B cell apoptment of autoimmune diseases	osis by B		
gru	AS	Los, M. et al., "Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases)," Blood 90:3118-3129, The American Society of Hematology (1997).						
m	АТ	<u>4</u>			trasser, "Apoptosis and auto ag (January 1999).	oimmune di	sease," I	nflamm. Res.
EXAMINER	Jh	W	Macis	()////		DATE CONST	DEREDO	
EXAMINER: Ir line through communication	citati	on if	not in co	nsidered, whet nformance and	her or not citation is in control to the considered. Include control to the contr	onformance py of this	e (with MPE s form wit	P 609. Draw h next

	OIPE CHT
(P.	JUN 2 5 2001
1	PADEMARK


FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

	_	Ω	ag a= 5	d£ 8
ATTY. DOCKET NO. 1735.0440001/RWE/BEC	APPLICATION 09/769,420	NON	<u> </u>	CE
APPLICANT	<u>* </u>	ניב	20	
CAI et al.		6	2[<
FILING DATE	GROUP	700/	01	m

INE	ORMATIC	IN DISCE	JSURE SIA	TEMENT		FILING DATE January 26, 2001		GROUP 1614		01	
	<u> </u>			U.S.	PZ	ATENT DOCUMENTS			5	3	
EXAMINER INITIAL		DOCUME NUMBER		DATE	N	IAME	CL	ASS	SUB- CLASS	FILING	DATE
	AA				L		<u> </u>			<u> </u>	
	AB										
	AC				┸		ļ			ļ	
	AD				╀		.			 	
	AE				\bot		—			 	
	AF				+		ļ			 	
	AG				\bot		 		ļ	 	
	AH				+		<u> </u>			 	
	AI				╀		-			 	
	AJ				+		-		ļ	-	
	AK			<u> </u>	L		<u> </u>		l	<u> </u>	
				FOREIG	N	PATENT DOCUMENTS	т—		· · · ·	· · · · · · · · · · · · · · · · · · ·	
EXAMINER INITIAL		DOCUMI		DATE	C	COUNTRY	CL.	ASS	SUB- CLASS	TRANSLA	ATION
···········	AL										Yes No
	AM										Yes No
	AN										Yes No
	AO										Yes No
	AP										Yes No
		OTI	HER (Inc.	luding Author,	T	itle, Date, Pertinent Page	es,	etc.)			
n	A R	<u>5</u> d	iabetes,	. and K.B. Elk multiple scle Press (January	erc	," Apoptosis in the effects and thyroiditis," <i>Cel</i> 999).	tor 1 De	phase	of autoir	nmune 13-21,	
f	AS					molecular mechanisms and 1. 237:529-536, Blackwell					
N	AT	<u>5</u> A	poptosis	of T Cells wi	ith	nometer Ultraviolet B Lighin Psoriatic Lesions," J . ess (February 1999).	ht (<i>Exp</i>	Narrov	v-Band UVF 189:711-	3) Induce	es e
EXAMINER	1/1/		7//	10/1/2			DATE	CONSI	DERED /	~~~	

EXAMINER! Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



communication to Applicant.

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1735.0440001/RWE/BEC 09/769,420 TAPPLICANT CAI et al. GROUP January 26, 2001 1614

				<u> </u>				
				v.s.	PATENT DOCUMENTS			
EXAMINER INITIAL		DOCU NUME	JMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	АВ					, , , ,		
	AC							
	AD							
	AE							
	AF							·
	AG							
	АН							
	AI							
	AJ							
	AK							
_				FOREIG	N PATENT DOCUMENTS			
EXAMINER INITIAL		DOCU NUME	JMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
-	AM							Yes No
	AN							Yes No
	AO		-					Yes No
	AP				·			Yes No
	,		OTHER (Incl	uding Author.	Title, Date, Pertinent Page	es. etc.)	<u> </u>	
gr	AR .	<u>6</u>	Savill, J.	, "Apoptosis	in resolution of inflammati yte Biology (1997).		eukocyte B	iol. 61:375-
77	Schmitt, E. et al., "The Bcl-xL and Bax-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation," Biochem. Cell Biol. 75:301-314, NRC Canada (1997).							
qu	-AT	<u>6</u>			caspase family of cysteine Council (1997).	proteases,	" Br. Med	. Bull.
EXAMINER	The	11/	11	Upla	,	DATE CONS	DEKED 8	82
EXAMINER: I	nitial citati	if re	eference co	nsidered, when	ther or not citation is in a not considered. Include co	conformand opy of thi	e with MPH s form wit	EP 609. Draw Th next

JUN 2 5 2001	
TAADEMARK OF	FC

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

		<u> </u>	age 🗁	٥
ATTY. DOCKET NO. 1735.0440001/RWE/BEC	APPLICATION 09/769,420	NIE	0	
APPLICANT CAI et al.		160	21	7
FILING DATE	GROUP	- <u>2</u>	- 1	T

					January 26, 2001	1614		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCU NUME	JMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
-	AA							
	AB							
	AC							
	AD					,		
	AE							
	AF		·					
	AG						ļ	
	AH	<u> </u>						
	AI				A.V.		<u> </u>	
	AJ		_					
	AK							
				FOREIG	N PATENT DOCUMENTS		,	
EXAMINER INITIAL		DOCU	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
	AM							Yes No
	AN							Yes No
	AO							Yes No
-	AP							Yes No
	•	, (OTHER (Inc.	Luding Author,	Title, Date, Pertinent Pag	es, etc.)		
Ta	[AR	7	Thornberr 5:R97-R10	y, N.A., "Casp 3, Current Bio	pases: key mediators of apopology Ltd. (1998).	ptosis," <i>C</i>	hemistry &	Biology
44	AS	7	with CD95	(Fas/Apo-1) m	"The molecular basis from a nutations," <i>J. Clin. Invest</i> ion (February 1999).	apoptotic (defects in 363, Ameri	patients can Society
M	AT	7	mediated a	apoptotic cell	Modulation by proinflammator death of synovial cells in Exp. Immunol. 114:119-128,	n patients	with rheu	matoid

EXAMINER / Kull of US

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

7

. "	O1 PE 25 2001 5	
N. C.	TADEMARY FORM	M PTO-1449 SISCLOSURE ST
	IN CHARLON D	IDOLODOKI DI

ATEMENT

APPLICATION NO. ATTY. DOCKET NO. 1735.0440001/RWE/BEC 09/769,420

APPLICANT CAI et al.

FILING DATE

GROUP

					FILING DATE January 26, 2001	1614		0/29 0/29		
				U.S	. PATENT DOCUMENTS			8		
EXAMINER INITIAL			UMENT IBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE		
	AA									
	AB									
	AC									
	AD						ļ			
	AE									
	AF						<u> </u>			
	AG			<u> </u>						
	AH									
	AI									
	AJ						<u> </u>	·		
	AK			<u> </u>						
				FOREI	GN PATENT DOCUMENTS		T			
EXAMINER INITIAL			UMENT IBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
	AL							Ye N		
	AM							Ye N		
	AN							Ye:		
	AO							Ye:		
	AP							Ye.		
			OTHER (Inc	luding Author	, Title, Date, Pertiner	nt Pages, etc.)				
Th	AR	8	necrosis,	" in Cell dea	eath: a new classificat. ath in biology and path 1, 1981, pp. 9-34.	ion separating ology, Bowen, I	apoptosis .D. and R	from .A. Lockshin,		
Ty	AS	<u>8</u>		Wyllie, A.H. et al., "Cell Death: The Significance of Apoptosis," <i>Intl. Rev.</i> Cytol. 68:251-306, Academic Press, Inc. (1980).						
J	AT	8	inhibits	et al., "Bisi T cell-mediat g Group (Janu	indolymaleimide VIII facted autoimmune diseases pary 1999).	cilitates Fas-m ," <i>Nature Med.</i>	ediated a 5:42-48,	poptosis and Nature		
EXAMINER) /	M	m)	MAD	//	DATE CONS	I BÎR P			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.